Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as exisulind, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving a chemotherapy drug before surgery may shrink the tumor so that it can be removed. PURPOSE: This phase II trial is studying how well neoadjuvant exisulind works in treating patients who are undergoing radical prostatectomy for stage II or stage III prostate cancer.

Key facts

Study ID

NCT00078910

Run by

National Cancer Institute (NCI)

People needed

130

Starts

2003-08-01

Expected to finish

2006-09-01

Last updated by the study team

2013-06-24

Who can join

Age: 40 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic Scottsdale — Scottsdale, Arizona, United States
• Mayo Clinic - Jacksonville — Jacksonville, Florida, United States
• Mayo Clinic Cancer Center — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.